serval:BIB_A25269F0E43E
Immunotherapeutic strategies for bladder cancer.
24384699
000336655000026
Chevalier
M.F.
author
Nardelli-Haefliger
D.
author
Domingos-Pereira
S.
author
Jichlinski
P.
author
Derré
L.
author
article
review
2014
Human Vaccines and Immunotherapeutics
2164-554X
2164-5515
journal
10
4
977-981
Bladder cancer is a common urologic malignancy with rising incidence in the elderly population. In most cases, bladder cancer is non-muscle-invasive at diagnosis and shows dramatically high recurrence rates, although current treatments often reduce the risk of disease progression. Immunotherapy using intravesical instillation of Bacillus Calmette-Guérin (BCG) remains the most effective therapy for patients with high risk tumors. However, BCG-therapy has important limitations including substantial adverse events and frequent treatment failure. Thus, it appears crucial to either improve or replace current therapy using new immunotherapeutic strategies. Here, we discuss the clinical trials that assessed therapeutic vaccination of bladder cancer patients using tumor associated antigens and we also argue for novel approaches arising from murine models. Vaccination routes to induce appropriate T-cell homing in the tumor site as well as the use of local immunostimulation to enhance recruitment of vaccine-induced T cells are discussed to highlight what we believe is a promising therapeutic vaccination strategy for patients with non-muscle-invasive bladder cancer.
Aged
Cancer Vaccines/administration & dosage
Cancer Vaccines/immunology
Clinical Trials as Topic
Humans
Immunotherapy/methods
T-Lymphocytes/immunology
Treatment Outcome
Urinary Bladder Neoplasms/therapy
eng
60_published
peer-reviewed
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
University of Lausanne
mailto:serval_help@unil.ch
http://www.unil.ch/serval
http://serval.unil.ch/disclaimer
https://serval.unil.ch/notice/serval:BIB_A25269F0E43E